The risks of damage to the developing nervous system of many chemicals are not known because these studies often require costly and time-consuming multi-generational animal experiments. Pluripotent stem cell-based systems can facilitate developmental neurotoxicity studies because disturbances in nervous system development can be modeled in vitro. In this study, neurons derived from embryonal carcinoma (EC) and induced pluripotent stem (iPS) cells, were first characterized to establish their suitability for developmental neurotoxicity studies. The EC stem cell line, TERA2.cl.SP-12, was differentiated into neurons that expressed voltage-gated sodium and potassium channels as well as ionotropic GABA and glutamate receptors. These cells could also fire action potentials when stimulated electronically. However spontaneous action potentials were not observed. In contrast, pre-differentiated neurons derived from iPS cells fired evoked and spontaneous action potentials. Furthermore, iPS cell-derived neurons also expressed a wide array of functional voltage- and ligand-gated ion channels. Antiepileptic drugs (AEDs) are associated with developmental neurotoxicity. These agents can cause congenital malformations, cognitive deficits and behavioral impairment in children as a result of in utero exposure. The impact of four major AEDs, namely phenobarbital, valproic acid, carbamazepine and lamotrigine, on cell viability, cell cycle and differentiation of TERA2.cl.SP-12 into neurons was studied. All AEDs tested reduced differentiating stem cell viability. Valproic acid and carbamazepine increased apoptosis and reduced cell proliferation. A brief exposure to phenobarbital, valproic acid and lamotrigine at the start of differentiation impaired the subsequent generation of neurons. Additionally, the effect of transient exposure to phenobarbital and carbamazepine on neuronal maturation of iPS-derived neurons was investigated. Exposure to both AEDs resulted in diminished membrane potentials and reduced the proportion of cells that were able to fire action potentials spontaneously in culture. The data from these studies suggest that impairments in proliferation, differentiation and maturation of neurons derived from human stem cells may be sensitive indicators of neurodevelopmental disruption by these drugs that can result from in utero exposure. Furthermore, these findings suggest that the use of human pluripotent stem cells and neurons derived from them can reduce the time, cost and the number of animals used in toxicological research.

La sclérose en plaques (SEP) est une maladie inflammatoire du système nerveux central (SNC). Le système immunitaire joue un rôle clé en SEP, cependant la contribution de molécules spécifiques reste à élucider. Nous avons identifié NKG2D, un récepteur immunitaire, comme joueur clef dans les interactions entre les cellules neurales et les lymphocytes dans la SEP. L’expression de ULBP4, un ligand de NKG2D, est élevée dans le cerveau des patients SEP, et présente sous forme soluble dans le liquide céphalorachidien (LCR). NKG2D joue un rôle délétère dans l’encéphalomyélite auto-immune expérimentale passive (EAE), un modèle de la SEP. MULT1, un ligand NKG2D, est élevé dans le SNC et le LCR au pic de la maladie EAE. Ainsi, nous avons émis l’hypothèse que la voie NKG2D module l’interaction entre les cellules neurales et les lymphocytes T. A l’aide d’imagerie en temps réel, nous avons montré que le blocage de NKG2D diminue les interactions stables entre les lymphocytes T CD8+ et les astrocytes humains in vitro. L’ajout d’ULBP4 soluble diminue les interactions stables entre ces lymphocytes et les astrocytes et ce avec une plus grande importance chez les patients SEP. Finalement, dans l’EAE, augmenter l’expression de MULT1 par injection intrathécale d’un vecteur viral augmente la sévérité des déficits moteurs. Cela corrèle avec une augmentation de la production d’IFNγ par les lymphocytes T infiltrants le SNC. Somme toute, NKG2D et ses ligands participent aux interactions entre les lymphocytes T et les cellules neurales en contexte de SEP et sont des cibles thérapeutiques potentielles à investiguer. / Multiple sclerosis is an inflammatory disease of the central nervous system (CNS). Although the key role of the immune system in MS is well established, the contribution of immune molecules remains incompletely unresolved. We identified NKG2D, an activating immune (co)receptor, as a key factor shaping the interactions between CNS and lymphocytes in MS. We have shown that expression of ULBP4, an NKG2D ligand, is elevated in brain from MS patients and increased in cerebrospinal fluid (CSF) as a soluble form. We have demonstrated that NKG2D contributes to disease progression in passive experimental autoimmune encephalomyelitis (EAE). We showed that one NKG2D ligand called MULT1 is upregulated in the CNS and in the CSF of EAE mice at disease peak. Thus, we hypothesized that the NKG2D pathway impacts the interactions between CNS cells and infiltrating T lymphocytes. Using our live-imaging co-culture model, we show that blocking NKG2D reduces stable interactions between CD8+ T lymphocytes and human astrocytes in vitro. Moreover, we observed that soluble ULBP4 decreases CD8 T cell-astrocyte stable interactions and modifies their behaviour with a stronger effect in MS patients. Finally, we saw in active EAE that increasing the expression of MULT1 in the CNS with an intrathecal injection of a viral vector increases motor deficits in mice. This correlates with a higher production of IFNγ by T lymphocytes. Thus, NKG2D and its ligands play important role in the interactions of CNS cells and T lymphocytes in the context of MS and are potential therapeutic targets to further investigate.